Objective LipUm has discovered a novel treatment of rheumatoid arthritis (RA) and potentially other inflammatory diseases by a uniquetherapeutic antibody directed towards the Bile Salt-Stimulated Lipase, which has been identified as a key target to block andthereby inhibit the inflammatory process and prevent joint destruction.The global prevalence of RA is 0.3-1%, and it is twice as common among woman than men, and the risk to develop thecondition increases by age. Frequently, other serious diseases are co-occurring with RA and according to the World HealthOrganisation 50% of patients in developed countries are unable to hold a full-time job within ten years after disease onset.The societal economic burden due to the disease is thus enormous, while health economic calculations estimate the cost forpharmaceuticals to less than 20% of the total cost. Still, the drug market value growth between 2014 and 2019 is expected toincrease by 55% to 30 billion USD.The introduction and use of biologicals such as the TNF-alfa inhibitors constituted a major achievement in the treatment, butwith time it has also been concluded that 1/3 of patients are not responding and another 1/3 experience only a transientimprovement. As these biologicals suppress the immune system such drugs should not be combined with otherimmunosuppressants, as it may create adverse health effects. Key opinion leaders have therefore pointed out the need fordrugs that have a complementary therapeutic mechanism.This is the gap that LipUm intends to fill and a tentative strategy is to apply for a orphan drug designation for juvenileidiopathic arthritis that affect children, frequently with extreme disability and poor quality of life. As an orphan drug our uniquebiological more rapidly could contribute to improved treatment of the 85,000 children diagnosed with the disease in Europe. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesclinical medicinerheumatologymedical and health scienceshealth sciencesinflammatory diseasesmedical and health sciencesclinical medicinegastroenterologyinflammatory bowel diseasemedical and health sciencesbasic medicineimmunology Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-1-2016-2017 Funding Scheme SME-1 - SME instrument phase 1 Coordinator LIPUM AB Net EU contribution € 50 000,00 Address TVISTEVAGEN 48 C 907 36 UMEA Sweden See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Norra Sverige Övre Norrland Västerbottens län Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00